Summary: People over 45 who use antihyperglycemic drugs to control type 2 diabetes have a higher risk of developing multiple sclerosis. However, people under the age of 45 and taking anti-hyperglycemic drugs have a lower risk of developing MS.

Source: University of Arizona

A new Arizona Health Sciences University study found that people over 45 with type 2 diabetes treated with antihyperglycemic drugs have a higher risk of developing atherosclerosis, and that antihyperglycemic exposure, especially in women, reduces the risk compared to people under 45. .

“Our findings reinforce the importance of a precision medicine approach to prevent MS in these vulnerable populations,” said lead researcher Kathleen Rogers, PhD, associate director of translational neuroscience at the Brain Science Innovation Center.

Multiple Sclerosis (MS) is a chronic, autoimmune neurological disease that affects the central nervous system and leads to severe physical and cognitive impairment. It is estimated that approximately 1 million adults in the US and more than 2.8 million worldwide live with MS.

In people with type 2 diabetes, there are studies linking metabolic abnormalities and MS, including a common autoimmunity driver. This is because anti-hyperglycemic therapies used to treat type 2 diabetes, including insulin, are used in MS.

“Previous research has shown that anti-hyperglycemic drugs have a neuroprotective effect on Alzheimer’s disease and other related dementias,” said Dr. Rogers. “For MS, we want to further investigate age and gender differences, particularly in men and women under 45 with type 2 diabetes.

This shows the shape of the head
Multiple Sclerosis (MS) is a chronic, autoimmune neurological disease that affects the central nervous system and leads to severe physical and cognitive impairment. The image is in the public domain.

Men over 45 years of age showed a slightly significant increase in the risk of MS and women over 45 years of age showed a significant increase in MS after antihyperglycemic exposure. In addition to age differences, the risk analysis conducted by the Department of Medicine showed that insulin exposure in patients over 45 years of age has a higher risk compared to other treatment methods.

In patients under 45 years of age, antihyperglycemic exposure prevents the development of MS.

The study used a US-based insurance claims database of 151 million participants, including more than 5 million people with type 2 diabetes and early- or late-onset MS. Researchers divided the data by age – patients with type 2 diabetes before and after the age of 45 – and gender to identify risk factors for MS in both populations, especially in women over 45.

The paper, “Age and Gender Differences in Antihyperglycemic Drug Exposure and Propensity Score-Associated Risk of Newly Diagnosed Multiple Sclerosis in Type 2 Diabetes Mellitus,” was recently published in the journal Hellion..

Co-authors Roberta Diaz Brinton, Ph.D., director and Regents Professor of the Bryan Center for Science Innovation; Francesca Vitali, PhD, assistant professor of neuroscience; Georgina Torandel-Harrow, doctoral candidate and graduate research assistant; and Gregory Brannigan, PhD, a third-year medical student in the UArizona College of Medicine – Tucson MD-PhD program.

Financial support This research was supported in part by the National Institute on Aging (P01AG026572, T32AG061897, R37AG053589) and the National Institutes of Health Division of Neurological Disorders and Stroke (R25NS107185).

So sclerosis and diabetes research news

Author: Gloria Bloomer
Source: University of Arizona
Contact: Gloria Bloomer – University of Arizona
Image: The image is in the public domain.

Preliminary study: Open Access.
Age and Gender Differences in Antihyperglycemic Drug Exposure and Risk of Newly Diagnosed Multiple Sclerosis in Propensity Score Patients with Type 2 Diabetes” by Kathleen Rogers et al Hellion.


Draft

Age and Gender Differences in Antihyperglycemic Drug Exposure and Risk of Newly Diagnosed Multiple Sclerosis in Propensity Score Patients with Type 2 Diabetes

watch out

This shows the face of a person against the background of the sunset

Background

The relationship between type 2 diabetes mellitus (T2D) treatment and exposure to anti-hyperglycemic drugs (A-HgM) in T2D patients and Multiple Sclerosis (MS) is not clear.

Methods

This retrospective cohort analysis used the Mariner claims database. Patient records were surveyed for MS diagnosis starting 12 months after diagnosis of T2D. Patients were required to be actively enrolled in Mariner claims records without a history of previous neurodegenerative disease six months before and at least three years after the diagnosis of T2D. Survival analysis was used to determine the association between A-HGM exposure and MS diagnosis. A propensity score approach was used to minimize measured and unmeasured selection bias. The analyzes were conducted between January 1 and April 28, 2021.

Findings

For T2D patients under 45 years of age, A-HgM exposure reduces the risk of developing MS (RR: 0.22, 95% CI: 0.17-0.29, p-value <0.001). Conversely, A-HgM exposure in patients older than 45 was associated with a higher risk in women (RR: 1.53, 95% CI: 1.39-1.69, p < 0.001) than in men (RR: 1.17, 95). %CI: 1.01–1.37, p = 0·04). Patients who developed MS had higher baseline comorbidities. The mean follow-up was 6.2 years with a standard deviation of 1.8 years.

Interpretation

In this study, A-HgM exposure in patients with T2D was associated with a reduced risk of developing MS in patients younger than 45 years, while exposure to A-HgM in patients older than 45 years was associated with newly diagnosed MS. It increases the risk of exposure, especially in women. .

Leave a Reply

Your email address will not be published. Required fields are marked *